News About: Goverment
KFDA not allows 3 COX-2 inhibitors to register.
Amid the safety problem of Celebrex, a COX-2 inhibitor, the KFDA said on Dec. 26 that the clinical studies of Bextra 100mg and 200mg (baldecoxcib) and the health registation of Palecoxib (Dynastat inj.) should not be ...
Time for pharmacy nighttime extra charge returned to 6 p.m.
Health Insurance Policy Review Commission determined in the 19th regular meeting that the time for the medical institutions and pharmacies to charge their night time extra services should be returned to 6 p.m. again f...
KFDA tough supervising distribution of biological drugs.
The distribution controls seem to be intensified to the manufacturers and retail and wholesalers of biological preparations, especially focusing on 22 checking items including temperature controls, shipment certifica...
Zydenar, an anti-impotence drug, to launch from Dec. 22.Zydenar, a 4th anti-impotence drug developed in the world by Dong-A, will be launched to the market from Dec. 22, which will be available under the physician's prescriptions at ...
|
KFDA to detect illegal substance for impotence.
A odd substance in the imported health functional food claimed as an anti-impotence has been identified by the KFDA.
The KFDA found a odd Viagra-like substance from the imported food supplement product and named it...
10 core technologies for the future Biotech markets presented in seminar.
In the seminar of "Announcement meeting for biotech industry fostering policy" at the KFI conference room on Dec. 19 under the sponsorship of the Ministry of Industry and Energy (MOIE), 10 core technologies were sugge...
NHI upper limited prices of 341 drug to cut down.
The upper limited NHI prices of the total 341 drugs including Boryung's Clinic tab. were reduced and about 200 new drugs including Daewoong's Neverfentin 300mg cap. were registered according to the revised NHI price l...
Toll manufacturing not allowed to poor rated drug manufacturers.
The rating work for the pharmaceutical manufacturers was completed recently, and the manufacturers rated at lower grades than A and B will be precluded the toll manufacturing qualification according to the Working Rul...
KFDA to approve clinical studies for 12 gene recombinant products.
The KFDA approved the clinical studies for 12 gene recombinant drugs including LB03002, a sustained type of human growth hormone developed by LG Life Science, Tifacogin inj. (Quintiles Korea), Remicade inj. 100m...
KFDA to check human placenta preparations.
Amid ever growing market trends of human placenta preparations, the KFDA collected 30 samples on the market to check for its quality.
The KFDA sample test came out amidst floating a harsh social controversy and eth...
